In development“We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the growing bacterial resistance to current classes of antibiotics.”
Convertible-loan fair-value losses drove the net loss; Innoviva credit maturities were extended amid a going-concern warning.
Latest 8-KDebt financingGovernance change ·
Innoviva subsidiary extends credit maturities and warrant expirations; FDA approval of a product candidate now triggers early termination of the voting agreement.
Sells it 18%, $74.4M a year“The product is a combination of sulbactam, a β-lactam antibiotic, and durlobactam, a novel β-lactamase inhibitor (“BLI”) with broad spectrum β-lactamase coverage including Classes A, C and D, that was specifically developed for the treatment of a variety of serious infections caused by carbapenem-resistant Acinetobacter”
Latest 10-KFY2025Positive ·
GIAPREZA and XACDURO lifted product sales, but at-cost Zai Lab supply limited margins; Armata investment gains drove GAAP earnings.
Revenue$411.3MYoY +14.7%
Net income$271.2Mvs $23.4M year ago
Latest 10-QQ3 FY2026Positive ·
XACDURO and GIAPREZA lift U.S. hospital sales; Armata markdowns overwhelm stronger operating earnings
Revenue$106.1MYoY −1.6%
Net income−$73.9Mvs $89.9M year ago
Latest 8-KEarningsGuidance reaffirmed ·
Lower royalties and ex-U.S. sales timing weighed on revenue; $139.5M in investment markdowns, mainly Armata, drove the net loss.
Latest 8-KLeadership change ·
Derek Small and Mark DiPaolo resign from the board to grow Syndeio BioSciences; Josephine Linden joins.
Latest 8-KShareholder voteExecutive pay ·
Stockholders approved the 2026 Equity Incentive Plan and elected five directors to one-year terms.
No companies have a recent 8-K matching these events.